The RUNX1 Research Program funds independent grants as well as grant programs in partnership with two prominent non-profit organizations fighting cancer: the Leukemia & Lymphoma Society (LLS) and Alex's Lemonade Stand Foundation (ALSF).



 Grant Programs

RRP currently has three grant-funding mechanisms: independent grants funded solely by RRP, and two separate co-funding partnership grants with LLS and ALSF.


RRP-LLS Program

The RUNX1 Research Program has partnered with the Leukemia and Lymphoma Society (LLS) to provide grants of $200,000 per year for three years for translational leukemia research related to the germline RUNX1 disorder.

Learn More →


RRP-ALSF Program

The RUNX1 Research Program has partnered with Alex’s Lemonade Stand for Childhood Cancer to fund new and innovative research into therapeutics that would prevent the transition from the disorder to leukemia.

Learn More →


RRP Independent Grants

These grants have been awarded to investigators who are either developing fundamental reagents/resources for the field or are early in their career and have committed to focusing their attention on RUNX1-FPD.

Learn More →


 Now Accepting Applications

RRP and Alex’s Lemonade Stand Foundation are pleased to announce that we are now accepting applications for the 2019 RUNX1 Early Career Investigator Grant Program.


Featured Grantees

The RUNX1 Research Program is proud to support innovative cancer research. Learn more about our grant awardees and their work.


Marc Raaijmakers, MD, PhD

Professor of Hematology, Erasmus MC Cancer Institute in Rotterdam, the Netherlands

Dr. Raaijmakers is a 2019 RRP/ALSF grantee. His research proposal aims to uncover whether RUNX1-FPD patients may be at heightened risk of blood cancer because of an unhealthy blood stem cell niche, which is the bone marrow. 

Learn more →


Zuzana Tothova, MD, PhD

Investigator, Dana-Farber Cancer Institute

The RUNX1 gene encodes a protein that falls into a specific category of proteins called transcription factors. Transcription factors are proteins that can control the output of protein production from other genes.

Learn more →



Bringing it All Together: Conferences

In October we hosted our our 3rd annual Scientific Meeting at the Aspen Meadows Resort in Colorado. Scientists and clinicians from around the world came together at this mountain retreat to discuss the latest research on RUNX1-FPD.


To maximize research speed, efficiency and ultimately outcomes, we aim to facilitate the exchange of information and resources between researchers.  We maintain a RUNX1-FPD-related reagent inventory listing, provide access to a database housing over 150 RUNX1-FPD patient NGS datasets and house an archive of videos from our annual conferences.  

img_stats 2.jpg

Breaking New Ground

The NIH has just initiated the first-ever longitudinal natural history study of RUNX1-FPD patients, with the aim of better understanding the clinical features of the disease, how these may relate to the different germline mutations and why some patients progress to blood cancer and others do not. This is a groundbreaking study and essential in our effort to find a cure.